OTCM
CHEOY
Market cap5.87bUSD
Oct 08, Last price
44.82USD
1D
-0.54%
1Q
5.56%
Jan 2017
1.20%
Name
Cochlear Ltd
Chart & performance
P/E
57.17
P/S
3.61
EPS
2.25
Div yield, %
3.06%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
9.35%
Revenues
2.33b
-0.36%
Net income
147m
-62.12%
CFO
368m
+54.88%
Dividend
Sep 22, 20260.46553 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cochlear Limited is a global healthcare company specializing in advanced auditory solutions. It develops and manufactures surgically implanted hearing devices for individuals of all ages, from children to adults, across the world. The company's diverse product range features cochlear implant systems, enhanced sound processor upgrades, bone conduction technology, and a variety of complementary accessories and related items. Founded in 1981, Cochlear Limited is headquartered in Sydney, Australia.
Related entities
Subsidiaries
COCHLEAR MEDICAL DEVICE COMPANY INDIA PRIVATE LIMITED
Key people
Sarah Thom
Chief Financial Officer · since 2025
Lisa Aubert
President - North America · since 2022
Anthony Bishop
President - EMEA · since 2025
Stuart Sayers
President, Asia Pacific & Latin America · since 2025
Greg Bodkin
Senior Vice President - Supply Chain & Operational Excellence · since 2018
Jennifer Hornery
Senior Vice President - People and Culture · since 2017
Brian Kaplan
Senior Vice President - Clinical Strategy and Innovation · since 2019
Jan Janssen
Chief Technology Officer · since 2017
Karen O'driscoll
Chief Information Officer · since 2023
Diggory Howitt
President, Chief Executive Officer, Executive Director · since 2018
Dean Phizacklea
Senior Vice President - Global Strategic Marketing · since 2016
Kristy Jo
Company Secretary · since 2025
Rob Mcgrory
Group General Counsel, Company Secretary · since 2025
Non-Executive Director · since 2022
Non-Executive Independent Chairman of the Board · since 2021
Caroline Clarke
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2020
Bruce Robinson
Non-Executive Independent Director · since 2016
IPO date
Dec 04, 1995
Employees
4,800
Domiciled in
AU
Incorporated in
AU
Headquarters & legal address
1 University Avenue
Macquarie University 2109
AU
Macquarie University 2109
AU
Previous name
Cochlear Pty Ltd
Previous name
Nexus Biomedical Pty Ltd
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||